DAIICHI SANKYO EUROPE adopts DATATRAK's eClinical platform for cardiovascular clinical study

DATATRAK International, Inc. (OTCQX: DATA), a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced that DAIICHI SANKYO EUROPE GmbH has selected DATATRAK's eClinical™ platform for a cardiovascular clinical study encompassing 80 sites and 1,200 patients across Europe. Reaping the benefits of a unified platform, DAIICHI SANKYO EUROPE GmbH will utilize DATATRAK's Electronic Data Capture solution in addition to web-based Patient Randomization, Drug Inventory Management, Lab Import and Auto-Coding Engine solutions. Also, study users will be able to view, manage and report on patient data via DATATRAK's dynamic, ad-hoc reporting module. As with all studies for this sponsor, DATATRAK will be producing CDISC SDTM compliant exports throughout the study.

"We have decided to use DATATRAK because the unified platform appealed to our needs. The ease in which for example IWRS or study drug management can be utilized with EDC within one solution will bring us significant benefit throughout the study. Furthermore, the built-in data export routines to SDTM and flexible ad-hoc reporting tools supporting our efforts in process control," said Paul-Egbert Reimitz, Director of Biostatistics and Data Operations at DAIICHI SANKYO EUROPE GmbH.

"We are delighted to have been awarded this new study by DAIICHI SANKYO EUROPE, whose adoption of DATATRAK ONE™ is a testament to both teams' hard work and success in implementing complex international clinical trials," said Laurence P. Birch, DATATRAK's Chairman of the Board. "We remain focused on providing our clients the benefits of increased patient safety, real-time data availability and management in addition to a completely unified user experience, ranging from investigative sites to Sponsors and CROs."

SOURCE DATATRAK International, Inc.